Targeting Serotonin 1a Receptors to Reverse Neurobehavioral Phenotypes

Neurolixis’ new drug targets serotonin 1A receptors, showing promise in preclinical studies for Fragile X syndrome, funded by a FRAXA grant for future clinical trials.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)